SEC Form 4 · accession 0001209191-15-069655
Revance Therapeutics, Inc. · RVNC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Arthur Peter Bertolino
Officer — EVP and Chief Medical Officer
Period of report
Sep 2, 2015
Accepted (ET)
Sep 4, 2015 · 4:16 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001479290
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Sep 2, 2015 | F | 3,699 | $30.48 | D | 41,754 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents the number of shares withheld by and surrendered to the Issuer on September 2, 2015, to satisfy tax withholding obligations that arose in connection with the vesting of the Restricted Stock Award ("RSA") for 9,844 shares. The RSA vests in four equal annual installments from September 2, 2014, subject to Reporting Person's Continuous Service (as defined in the Issuer's 2014 Inducement Plan) on each vesting date.